Mechanism of Action of Tofacitinib (Xeljanz)
Introduction Tofacitinib is an oral Janus kinase (JAK) inhibitor, primarily targeting JAK1 and JAK3. It blocks intracellular signaling of multiple inflammatory cytokines and is approved for rheumatoid arthritis (RA), psoriatic arthritis (PsA), ulcerative colitis (UC), and other immune-mediated diseases. Step-by-Step Mechanism of Action Pharmacokinetic Parameters Parameter Value Route Oral Bioavailability ~74% Time to Peak (Tmax) … Read more